Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients. [artículo]
Por: Fernández Ruiz, Mario [Medicina Interna]
| Lumbreras Bermejo, Carlos [Medicina Interna] | Arrazola Martínez, María Pilar [Medicina Preventiva] | López Medrano, Francisco [Enfermedades Infecciosas] | Andrés Belmonte, Amado [Nefrología] | Morales Cerdán, José María [Nefrología] | De Juanes Pardo, José Ramón [Medicina Preventiva] | Aguado García, José María [Enfermedades Infecciosas].
Colaborador(es): Servicio de Medicina Interna | Servicio de Medicina Preventiva y Salud Pública | Servicio de Nefrología | Instituto de Investigación imas12.
Tipo de material: 
ArtículoEditor: Transplant infectious disease : an official journal of the Transplantation Society, 2015Recursos en línea: Solicitar documento Resumen: Background: Safety concerns have been raised about the use of adjuvanted vaccines after kidney transplantation.
Methods: We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010.
Results: Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination.
Conclusion: Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC17084 (Navegar estantería) | Disponible |
Formato Vancouver:
Fernández Ruiz M, Lumbreras C, Arrazola MP, López Medrano F, Andrés A, Morales JM et al. Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients. Transpl Infect Dis. 2015 Apr;17(2):314-21. doi: 10.1111/tid.12355. Epub 2015 Mar 2. .
PMID: 25728936
Contiene 30 referencias
Background: Safety concerns have been raised about the use of adjuvanted vaccines after kidney transplantation.
Methods: We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010.
Results: Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination.
Conclusion: Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.
No hay comentarios para este ejemplar.